GeneDx Holdings Corp.
$ 65.11
-5.58%
31 Jul - close price
- Market Cap 1,932,988,000 USD
- Current Price $ 65.11
- High / Low $ 70.83 / 64.88
- Stock P/E N/A
- Book Value 8.57
- EPS -2.66
- Next Earning Report 2026-08-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -0.30 %
- 52 Week High 170.87
- 52 Week Low 32.21
About
Sema4 Holdings Corp. The company is headquartered in Stamford, Connecticut.
Analyst Target Price
$81.78
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-04 | 2026-02-23 | 2025-10-28 | 2025-07-29 | 2025-04-30 | 2025-02-18 | 2024-10-29 | 2024-07-30 | 2024-04-29 | 2024-02-20 | 2023-10-30 | 2023-08-08 |
| Reported EPS | -0.28 | 0.14 | 0.49 | 0.5 | 0.27 | 0.6353 | 0.04 | -0.1 | -0.33 | -0.69 | -0.82 | -1.77 |
| Estimated EPS | -0.0495 | 0.12 | 0.42 | 0.11 | 0.09 | 0.1033 | -0.21 | -0.3 | -0.67 | -0.75 | -1.31 | -1.31 |
| Surprise | -0.2305 | 0.02 | 0.07 | 0.39 | 0.18 | 0.532 | 0.25 | 0.2 | 0.34 | 0.06 | 0.49 | -0.46 |
| Surprise Percentage | -465.6566% | 16.6667% | 16.6667% | 354.5455% | 200% | 515.0048% | 119.0476% | 66.6667% | 50.7463% | 8% | 37.4046% | -35.1145% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-03 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.19 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: WGS
2026-08-02 16:09:47
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of investors who purchased securities between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made materially false and misleading statements regarding the importance of Fabric Genomics, its declining margins, and non-durable reimbursement rates. Investors who suffered losses are encouraged to contact the firm to explore their options, with a lead plaintiff deadline of August 3, 2026.
2026-08-01 22:09:47
The Rosen Law Firm is reminding investors who purchased common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025, and May 4, 2026, of the August 3, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that GeneDx made misleading statements regarding the positive impact of its Fabric acquisition on the company's financials and operations, when in reality, significant problems existed that negatively impacted the business. Investors with losses exceeding $100,000 are encouraged to join the class action to seek compensation.
2026-08-01 06:41:43
Kahn Swick & Foti, LLC (KSF) has reminded investors of GeneDx Holdings Corp. (NASDAQ: WGS) with substantial losses that they have until August 3, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that GeneDx and its executives failed to disclose material information during the Class Period, leading to a significant drop in stock price after the company reported lower-than-expected financial results and an impairment loss related to its Fabric Genomics acquisition. Investors who purchased shares between April 16, 2025, and May 4, 2026, are encouraged to contact KSF for legal counsel.
2026-08-01 06:39:44
Kahn Swick & Foti, LLC (KSF) is reminding investors in GeneDx Holdings Corp. (NasdaqGS: WGS) that they have until August 3, 2026, to apply for lead plaintiff in a securities class action lawsuit. The lawsuit alleges that GeneDx and its executives made false and misleading statements regarding the company's financial performance, including deteriorating adjusted gross margins and missed revenue estimates. These alleged misrepresentations led to a significant drop in GeneDx's stock price.
2026-07-31 18:40:10
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against GeneDx Holdings Corp. (NASDAQ:WGS) for alleged federal securities law violations. The lawsuit claims GeneDx made false and misleading statements about its business, leading to a significant drop in stock price after the company reported poor financial results and lowered revenue guidance. Investors who purchased WGS common stock between April 16, 2025, and May 4, 2026, have until August 3, 2026, to apply to be lead plaintiff.
2026-07-31 11:10:14
Robbins Geller Rudman & Dowd LLP announced a Monday, August 3, 2026 deadline for investors who purchased GeneDx Holdings Corp. (WGS) common stock between April 16, 2025, and May 4, 2026, to seek appointment as lead plaintiff in a class action lawsuit. The lawsuit alleges that GeneDx made false or misleading statements regarding the viability of its acquisition, Fabric Genomics, which led to a significant stock drop after the company revealed an impairment loss and reduced earnings projections. Investors who suffered substantial losses are encouraged to contact the firm to lead the class action.
